Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dexpramipexole

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

Biogen Idec launches online multiple sclerosis programme

MS Blueprint aims to help people with MS develop a personalised support plan

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Exelixis axes staff as lead cancer programme fails

Plans to cut workforce by 70% after cabozantinib disappoints in phase III

- PMLiVE

Pharma takes the ALS Ice Bucket Challenge

GSK, Evotec and Biogen Idec participate in the social media sensation

- PMLiVE

Amgen hit as Kyprolis fails myeloma study

Inability to improve overall survival could dent expanded use prospects

- PMLiVE

Nexavar fails late-stage breast cancer trial

Bayer’s oncology drug unable to improve progression free survival in new indication

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

Lundbeck’s desmoteplase flunks phase III stroke trial

No better than placebo at improving disability symptoms

- PMLiVE

Lilly’s Cyramza disappoints in liver cancer

Fails to improve overall survival by significant margin

- PMLiVE

Second darapladib failure disappoints GSK

Drug unable to demonstrate effectiveness in acute coronary syndrome

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links